// Auto-generated - do not edit
export const substanceName = "2-Fluorodeschloroketamine";
export const sources = [{"id":"isomerdesign","fileName":"ISOMERDESIGN - 2-Fluorodeschloroketamine.md","displayName":"Isomer Design","size":859},{"id":"protestkit","fileName":"PROTESTKIT - 2-Fluorodeschloroketamine.json","displayName":"Protest Kit","size":5043},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - 2-Fluorodeschloroketamine.md","displayName":"PsychonautWiki","size":24247},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - 2-Fluorodeschloroketamine.md","displayName":"TripSit Factsheets","size":570},{"id":"wikipedia","fileName":"WIKIPEDIA - 2-Fluorodeschloroketamine.md","displayName":"Wikipedia","size":5275}];
export const contents: Record<string, string> = {
  "isomerdesign": `# 2-Fluorodeschloroketamine
*Source: https://isomerdesign.com/PiHKAL/explore.php?id=981*

## Chemical Data

**IUPAC Name:** 2-(2-Fluorophenyl)-2-(methylamino)cyclohexan-1-one

**Molecular Formula:** C13H16FNO

**Molecular Weight:** 221.271

**SMILES:** \`CNC1(CCCCC1=O)c1ccccc1F\`

**InChI:** \`InChI=1S/C13H16FNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3\`

## External References

- [](https://en.wikipedia.org/wiki/Markush_structure)
- [43515873](https://www.chemspider.com/Chemical-Structure.43515873.html/)
- [13771618](https://pubchem.ncbi.nlm.nih.gov/compound/13771618)
- [Q23796153](https://www.wikidata.org/wiki/Q23796153)
- [2-Fluorodeschloroketamine](https://en.wikipedia.org/wiki/2-Fluorodeschloroketamine)
- [List of arylcyclohexylamines](https://en.wikipedia.org/wiki/Arylcyclohexylamine#List_of_arylcyclohexylamines)
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/2-Fluorodeschloroketamine",
  "experiencesUrl": "https://www.reddit.com/search/?q=2-FDCK",
  "name": "2-FDCK",
  "aliases": [
    "2-fl-2'-oxo-pcm",
    "2-fluorodeschloroketamine",
    "2f-dck",
    "2f-ket",
    "2f-ketamine",
    "2fdck",
    "2fket",
    "fluoroketamine"
  ],
  "aliasesStr": "2-fl-2'-oxo-pcm,2-fluorodeschloroketamine,2f-dck,2f-ket,2f-ketamine,2fdck,2fket,fluoroketamine",
  "summary": "Dissociative anesthetic of the arylcyclohexylamine class. Seemingly on par with ketamine in dosage. Longer onset than the prior.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Arylcyclohexylamines"
    ],
    "psychoactive": [
      "Dissociatives"
    ]
  },
  "toxicity": [
    "exact toxic dosage is unknown"
  ],
  "addictionPotential": "moderately addictive with a high potential for abuse",
  "tolerance": {
    "full": "develops with prolonged and repeated use",
    "half": "3 - 7 days",
    "zero": "1 - 2 weeks"
  },
  "crossTolerances": [
    "dissociative"
  ],
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "5 mg"
        },
        {
          "name": "Light",
          "value": "10 - 25 mg"
        },
        {
          "name": "Common",
          "value": "25 - 70 mg"
        },
        {
          "name": "Strong",
          "value": "70 - 140 mg"
        },
        {
          "name": "Heavy",
          "value": "140 mg+"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.25 - 0.83 hours"
        },
        {
          "name": "Peak",
          "value": "0.83 - 1.67 hours"
        },
        {
          "name": "Total",
          "value": "2.5 - 5.0 hours"
        },
        {
          "name": "After effects",
          "value": "3.0 - 8.0 hours"
        }
      ]
    },
    {
      "name": "Insufflated",
      "dosage": [
        {
          "name": "Threshold",
          "value": "5 mg"
        },
        {
          "name": "Light",
          "value": "10 - 45 mg"
        },
        {
          "name": "Common",
          "value": "45 - 100 mg"
        },
        {
          "name": "Strong",
          "value": "100 - 175 mg"
        },
        {
          "name": "Heavy",
          "value": "175 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.02 - 0.05 hours"
        },
        {
          "name": "Come up",
          "value": "0.08 - 0.17 hours"
        },
        {
          "name": "Total",
          "value": "1.5 - 3.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 4.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Caution"
    },
    {
      "name": "Benzos",
      "status": "Caution"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Cocaine",
      "status": "Caution"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "DXM",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MAOIs",
      "status": "Caution"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MMC class",
      "status": "Unsafe"
    },
    {
      "name": "MXE",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": null,
  "categorized_effects": {
    "Physical effects": [],
    "Mental effects": [],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "psychonautwiki": `# 2-Fluorodeschloroketamine
*Source: https://psychonautwiki.org/wiki/2-Fluorodeschloroketamine*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 5 mg
- Light: 10 - 25 mg
- Common: 25 - 70 mg
- Strong: 70 - 140 mg
- Heavy: 140 mg+

**Duration:**
- Total: 2.5 - 5.0 hours
- Onset: 15 - 50 minutes
- Peak: 50 - 100 minutes
- After effects: 3 - 8 hours

### Insufflated

**Dosage:**
- Threshold: 5 mg
- Light: 10 - 45 mg
- Common: 45 - 100 mg
- Strong: 100 - 175 mg
- Heavy: 175 mg +

**Duration:**
- Total: 1.5 - 3 hours
- Onset: 1 - 3 minutes
- Come up: 5 - 10 minutes
- After effects: 1 - 4 hours

**2-Fl-2'-Oxo-PCM** (also known as **2-Fluorodeschloroketamine** , **2-FDCK** , and inaccurately as **2-Fluroketamine** , **Fluoroketamine** , and **2-FK** and known as CAS number: 111982-50-4) is a lesser-known novel [dissociative](https://psychonautwiki.org/wiki/Dissociative) substance of the [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) class. It is chemically similar to [ketamine](https://psychonautwiki.org/wiki/Ketamine) and [deschloroketamine](https://psychonautwiki.org/wiki/Deschloroketamine) (DCK). It is thought to act as an [NMDA receptor antagonist](https://psychonautwiki.org/wiki/NMDA_receptor_antagonist) , although research is currently limited.

The origins of 2F-DCK are not well-documented. It appears to have first become available for sale on the online [research chemical](https://psychonautwiki.org/wiki/Research_chemical) market in 2017, in which it was marketed as a legal replacement for [ketamine](https://psychonautwiki.org/wiki/Ketamine) . It was released after the successful introduction of a similar ketamine analog, [deschloroketamine](https://psychonautwiki.org/wiki/Deschloroketamine) .

[Subjective effects](https://psychonautwiki.org/wiki/Subjective_effects) include [sedation](https://psychonautwiki.org/wiki/Sedation) , [motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss) , [pain relief](https://psychonautwiki.org/wiki/Pain_relief) , [internal hallucinations](https://psychonautwiki.org/wiki/Internal_hallucinations) , [conceptual thinking](https://psychonautwiki.org/wiki/Conceptual_thinking) , [euphoria](https://psychonautwiki.org/wiki/Euphoria) , and [dissociation](https://psychonautwiki.org/wiki/Disconnective_effects) . Dissociation is a complex mental state characterized by perceptual distortions and feelings of detachment from the environment and one's self. 2F-DCK's effects are reported to be similar to those of ketamine. Like ketamine, 2F-DCK's effects are highly dose-dependent, with lower doses producing [alcohol-like](https://psychonautwiki.org/wiki/Alcohol) intoxication and higher doses producing [hallucinogenic](https://psychonautwiki.org/wiki/Hallucinogen) out-of-body states (also known as a "k-hole").

Limited data exist on the pharmacology, metabolism, or toxicity of 2-FDCK. It has an extremely brief history of human use. It is strongly advised to use [harm reduction practices](https://psychonautwiki.org/wiki/Harm_reduction_practices) if using this substance.

## Chemistry

2-Fluorodeschloroketamine, or 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone, is classed as an [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) drug. Arylcyclohexylamines drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group. 2-FDCK contains a phenyl ring bonded to a cyclohexane ring substituted with a ketone group (cyclohexanone). An amino methyl chain (-N-CH 3 ) is bound to the adjacent alpha carbon (R 2 ) of the cyclohexanone ring. Additionally, the phenyl ring is substituted at R 2 with a fluorine group.

2-Fluorodescholoroketamine is a chiral molecule and is often produced as a racemate. Des- is a prefix used in chemistry to denote the absence of a functional group (in this case "chloro") hence 2-FDCK is named for containing a fluorine substitution at its phenyl ring rather than the chlorine which is found in [ketamine](https://psychonautwiki.org/wiki/Ketamine) .

## Pharmacology

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) [dissociatives](https://psychonautwiki.org/wiki/Dissociative) such as [DCK](https://psychonautwiki.org/wiki/DCK) and [ketamine](https://psychonautwiki.org/wiki/Ketamine) . With this in mind, 2-Fluorodeschloroketamine is thought to act as an [NMDA receptor antagonist](https://psychonautwiki.org/wiki/NMDA_receptor_antagonist) .

NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually this substance's equivalent of the “ [K-hole](https://psychonautwiki.org/wiki/Visual_disconnection#Holes.2C_spaces_and_voids) .”

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Pain relief](https://psychonautwiki.org/wiki/Pain_relief)**
- **[Spontaneous physical sensations](https://psychonautwiki.org/wiki/Spontaneous_physical_sensations)**
- **[Physical euphoria](https://psychonautwiki.org/wiki/Physical_euphoria)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)**
- **[Motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss)**
- **[Nausea](https://psychonautwiki.org/wiki/Nausea)**
- **[Perception of bodily lightness](https://psychonautwiki.org/wiki/Perception_of_bodily_lightness)**
- **[Physical autonomy](https://psychonautwiki.org/wiki/Physical_autonomy)**
- **[Spatial disorientation](https://psychonautwiki.org/wiki/Spatial_disorientation)**
- **[Tactile suppression](https://psychonautwiki.org/wiki/Tactile_suppression)**
- **[Orgasm suppression](https://psychonautwiki.org/wiki/Orgasm_suppression)** ### Disconnective effects
 
- - **[Tactile disconnection](https://psychonautwiki.org/wiki/Tactile_disconnection)**
- **[Visual disconnection](https://psychonautwiki.org/wiki/Visual_disconnection)** - This eventually results in 2-Fluorodeschloroketamine's equivalent of the " [k-hole](https://en.wikipedia.org/wiki/K-hole) " or, more specifically, *[holes, spaces and voids](https://psychonautwiki.org/wiki/Visual_disconnection#Holes.2C_spaces_and_voids)* alongside of *[structures](https://psychonautwiki.org/wiki/Visual_disconnection#Structures)* .
- **[Consciousness disconnection](https://psychonautwiki.org/wiki/Consciousness_disconnection)** ### Visual effects
 
- #### Suppression
 
- **[Double vision](https://psychonautwiki.org/wiki/Double_vision)**
- **[Frame rate suppression](https://psychonautwiki.org/wiki/Frame_rate_suppression)**
- **[Pattern recognition suppression](https://psychonautwiki.org/wiki/Pattern_recognition_suppression)**
- **[Visual acuity suppression](https://psychonautwiki.org/wiki/Visual_acuity_suppression)**
 
#### Distortions
 
- **[Environmental cubism](https://psychonautwiki.org/wiki/Environmental_cubism)**
- **[Environmental orbism](https://psychonautwiki.org/wiki/Environmental_orbism)**
- **[Perspective distortions](https://psychonautwiki.org/wiki/Perspective_distortions)**
- **[Scenery slicing](https://psychonautwiki.org/wiki/Scenery_slicing)**
 
#### Geometry
 
#### Hallucinatory states
 
- **[Internal hallucination](https://psychonautwiki.org/wiki/Internal_hallucination)** ( *[autonomous entities](https://psychonautwiki.org/wiki/Autonomous_entities)* ; *[settings, sceneries, and landscapes](https://psychonautwiki.org/wiki/Settings,_sceneries,_and_landscapes)* ; *[perspective hallucinations](https://psychonautwiki.org/wiki/Perspective_hallucinations)* and *[scenarios and plots](https://psychonautwiki.org/wiki/Scenarios_and_plots)* ) ### Cognitive effects
 
- The cognitive effects of 2-FDCK are best compared to [ketamine](https://psychonautwiki.org/wiki/Ketamine) and some users find the effects nearly indistinguishable. Subjectively, the experience on 2-FDCK tends to be paced at a slower rate alongside distinct psychedelic effects which differ slightly from ketamine. Some users also report that 2-FDCK can sometimes produce slightly more confusion and generally more difficulty to "hole" with higher dosages, while others don't seem to notice this and instead treat it being equally enjoyable whilst also retaining the same antidepressant effects that ketamine produces. 
- **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)**
- **[Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing)**
- **[Conceptual thinking](https://psychonautwiki.org/wiki/Conceptual_thinking)**
- **[Creativity enhancement](https://psychonautwiki.org/wiki/Creativity_enhancement)**
- **[Déjà vu](https://psychonautwiki.org/wiki/D%C3%A9j%C3%A0_vu)**
- **[Depersonalization](https://psychonautwiki.org/wiki/Depersonalization)**
- **[Derealization](https://psychonautwiki.org/wiki/Derealization)**
- **[Disinhibition](https://psychonautwiki.org/wiki/Disinhibition)**
- **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)**
- **[Immersion enhancement](https://psychonautwiki.org/wiki/Immersion_enhancement)**
- **[Analysis suppression](https://psychonautwiki.org/wiki/Analysis_suppression)**
- **[Introspection](https://psychonautwiki.org/wiki/Introspection)**
- **[Memory suppression](https://psychonautwiki.org/wiki/Memory_suppression)** 
- **[Ego death](https://psychonautwiki.org/wiki/Ego_death)**
- **[Amnesia](https://psychonautwiki.org/wiki/Amnesia)**
- **[Time distortion](https://psychonautwiki.org/wiki/Time_distortion)**
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)** ### Auditory effects
 
- - **[Distortions](https://psychonautwiki.org/wiki/Auditory_distortion)**
- **[Hallucinations](https://psychonautwiki.org/wiki/Auditory_hallucinations)**
- **[Suppression](https://psychonautwiki.org/wiki/Auditory_suppression)**
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: 2-Fluorodeschloroketamine](https://www.erowid.org/experiences/subs/exp_2Fluorodeschloroketamine.shtml)

## Toxicity and harm potential

The toxicity and long-term health effects of recreational 2-Fluorodeschloroketamine use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-Fluorodeschloroketamine has very little history of human usage. Anecdotal evidence from people who have tried 2-Fluorodeschloroketamine within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this drug.

### Dependence and abuse potential

As with other NMDA receptor antagonists, the chronic use of 2-Fluorodeschloroketamine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [withdrawal effects](https://psychonautwiki.org/wiki/Withdrawal_effects) may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-Fluorodeschloroketamine develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 2-Fluorodeschloroketamine presents cross-tolerance with all [dissociatives](https://psychonautwiki.org/wiki/Dissociative) , meaning that after the consumption of 2-Fluorodeschloroketamine all [dissociatives](https://psychonautwiki.org/wiki/Dissociative) will have a reduced effect.

### Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 2-Fluorodeschloroketamine seems to exhibit almost identical bladder and urinary tract problems to those found within [ketamine](https://psychonautwiki.org/wiki/Ketamine) but to a lesser extent. This is because 2-Fluorodeschloroketamine is a little more potent than ketamine, meaning that less of the drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and include:

- **Urinary frequency** - Urinary frequency is the need to empty the bladder every few minutes.
- **Urinary urgency** - This can be described as a sudden, compelling need to urinate.
- **Urinary pressure** - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
- **Pelvic and bladder pain** - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
- **Hematuria** - Hematuria is visible blood in the urine.
- **Incontinence** - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 2-Fluorodeschloroketamine on a daily or even weekly basis and manually limiting one's usage of the substance.

### Dangerous interactions

***Warning:*** *Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).*

*Always conduct independent research (e.g. [Google](https://www.google.com) , [DuckDuckGo](https://www.duckduckgo.com) , [PubMed](https://pubmed.ncbi.nlm.nih.gov/) ) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from [TripSit](https://combo.tripsit.me) .*

- **Benzodiazepines** - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position.
- **MAOIs** - MAO-B inhibitors appear to increase the potency of ketamine. MAO-A inhibitors have some negative reports associated with the combination but there isn't much information available
- **Alcohol** - Both substances cause ataxia and bring a very high risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
- **GHB** - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
- **GBL** - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
- **Opioids** - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
- **Tramadol** - Potential increased risk of seizures.
- **Grapefruit** - Grapefruit juice significantly increases oral absorption of ketamine. This may result in the user having double the concentration of ketamine in their system compared to normal. The ketamine may also have a longer duration of effect. It is likely that this property extends to 2F-DCK as well.

## Legal status

- **Austria:** 2-Fluorodeschloroketamine is illegal to possess, produce and sell under the NPSG. (Neue-Psychoaktive-Substanzen-Gesetz Österreich)
- **Canada:** 2-Fluorodeschloroketamine is not specifically listed in the Controlled Drugs and Substances Act (CDSA) but could be considered controlled under schedule I: "14 Phencyclidine (1-(1-phenylcyclohexyl)piperidine), its salts, derivatives and analogues and salts of derivatives and analogues, including: (1) Ketamine . . ." It could presumably be considered an analogue of PCP due to its structural similarity to ketamine.
- **Czech Republic:** 6-APB is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of *Nařízení vlády č. 463/2013 Sb.* )
- **Germany:** 2-Fluorodeschloroketamine is controlled under the NpSG ( *New Psychoactive Substances Act* ) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- **Italy:** 2-Fluorodeschloroketamine is a Schedule I ( *Tabella I* ) controlled substance.
- **Latvia:** 2-Fluorodeschloroketamine is illegal in Latvia.
- **Switzerland:** 2-Fluorodeschloroketamine is a controlled substance specifically named under Verzeichnis E.
- **Turkey:** 2-Fluorodeschloroketamine is a classed as drug and is illegal to possess, produce, supply, or import.
- **United Kingdom:** 2-Fluorodeschloroketamine is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 2-Amino-2-phenylcyclohexanone substituted in the phenyl ring with a halide substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Designer drug](https://psychonautwiki.org/wiki/Designer_drug)
- [Dissociatives](https://psychonautwiki.org/wiki/Dissociatives)
- [Arylcyclohexylamines](https://psychonautwiki.org/wiki/Arylcyclohexylamines)
- [Deschloroketamine](https://psychonautwiki.org/wiki/Deschloroketamine) ( *O-PCM* )
- [MXE](https://psychonautwiki.org/wiki/MXE)

## External links

- [2-Fluorodeschloroketamine (Wikipedia)](https://en.wikipedia.org/wiki/2-Fluorodeschloroketamine)
- [2-Fluorodeschloroketamine (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=981)
- [The Big & Dandy 2-Fluoroketamine Thread (Bluelight)](http://www.bluelight.org/vb/threads/776753-The-Big-amp-Dandy-2-Fluoroketamine-Thread)

## References
1. ↑ Moghimi, A., Rahmani, S., Zare, R., Sadeghzadeh, M. (18 July 2014).["Synthesis of 2-(2-Fluorophenyl)-2-methylamino-Cyclohexanone as a New Ketamine Derivative"](https://doi.org/10.1080/00397911.2014.885053).*Synthetic Communications*.**44**(14): 2021–2028.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1080/00397911.2014.885053](//doi.org/10.1080%2F00397911.2014.885053).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0039-7911](//www.worldcat.org/issn/0039-7911).
2. ↑ The Big & Dandy 2-Fluoroketamine Thread | [http://www.bluelight.org/vb/threads/776753-The-Big-amp-Dandy-2-Fluoroketamine-Thread](http://www.bluelight.org/vb/threads/776753-The-Big-amp-Dandy-2-Fluoroketamine-Thread)
3. ↑ Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Neuvonen, P. J., Olkkola, K. T. (June 2012). "S-ketamine concentrations are greatly increased by grapefruit juice".*European Journal of Clinical Pharmacology*.**68**(6): 979–986.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s00228-012-1214-9](//doi.org/10.1007%2Fs00228-012-1214-9).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1432-1041](//www.worldcat.org/issn/1432-1041).
4. ↑ [RIS - Neue-Psychoaktive-Substanzen-Verordnung - Bundesrecht konsolidiert, Fassung vom 21.07.2022](https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=20007642)
5. ↑ Controlled Drugs and Substances Act (S.C. 1996, c. 19) | [http://laws-lois.justice.gc.ca/PDF/C-38.8.pdf](http://laws-lois.justice.gc.ca/PDF/C-38.8.pdf)
6. ↑ [https://www.zakonyprolidi.cz/cs/2013-463?text=o+seznamech+n%C3%A1vykov%C3%BDch](https://www.zakonyprolidi.cz/cs/2013-463?text=o+seznamech+n%C3%A1vykov%C3%BDch)
7. ↑ ["Anlage NpSG"](https://www.gesetze-im-internet.de/npsg/anlage.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
8. ↑ ["Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes"](http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf)(PDF).*Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27*(in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
9. ↑ ["§ 4 NpSG"](https://www.gesetze-im-internet.de/npsg/__4.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
10. ↑ MINISTERO DELLA SALUTE, DECRETO 13 marzo 2020 [https://www.gazzettaufficiale.it/eli/id/2020/03/30/20A01820/sg](https://www.gazzettaufficiale.it/eli/id/2020/03/30/20A01820/sg)
11. ↑ [http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc](http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc)
12. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
13. ↑ ["Cumhurbaşkanı Kararı: Karar Sayısı: 1335"](https://resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf)(PDF).*Resmî Gazete, Sayı: 30837*(in Turkish). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published July 20, 2019). July 19, 2020.
14. ↑ [The Misuse of Drugs Act 1971 (Amendment) Order 2013](https://www.legislation.gov.uk/uksi/2013/239/introduction/made)NewPP limit report Cached time: 20251218074853 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.064 seconds CPU time usage: 0.276 seconds Real time usage: 0.527 seconds Preprocessor visited node count: 1608/1000000 Post‐expand include size: 112588/2097152 bytes Template argument size: 12126/2097152 bytes Highest expansion depth: 11/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 13505/5000000 bytes Lua time usage: 0.170/7 seconds Lua virtual size: 7.18 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 22Transclusion expansion time report (%,ms,calls,template) 100.00% 387.353 1 -total 27.25% 105.539 2 Template:Cite_journal 22.70% 87.935 5 Template:Cite_web 13.98% 54.134 2 Template:Further 11.67% 45.207 1 Template:SubstanceBox/2-FDCK 10.48% 40.586 1 Template:SubstanceBox 8.47% 32.793 1 Template:Effects/base 7.55% 29.257 1 Template:Effect_list 6.66% 25.790 2 Template:Citation 6.59% 25.519 2 Template:Effect_column`,
  "tripsit-factsheets": `# 2-FDCK
*Source: TripSit Factsheets (tripsit.me)*

## Summary

Dissociative anesthetic of the arylcyclohexylamine class. Seemingly on par with ketamine in dosage. Longer onset than the prior.

## Classification
- **Categories:** tentative, dissociative, habit-forming
- **Also known as:** 2f-ketamine, 2f-ket, 2-fluorodeschloroketamine, 2-fl-2'-oxo-pcm, 2f-dck, 2fket, 2fdck

## Dosage

### Insufflated
- **Common:** 50-100mg
- **Light:** 20-50mg
- **Strong:** 100-175mg+

## Duration
- **Onset:** 20-40 minutes
- **Duration:** 1-3 hours
- **After Effects:** 1-3 hours
`,
  "wikipedia": `# 2-Fluorodeschloroketamine
*Source: https://en.wikipedia.org/wiki/2-Fluorodeschloroketamine*

2-Fluorodeschloroketamine (also known as 2'-Fl-2-Oxo-PCM, fluoroketamine, and 2-FDCK) is a dissociative anesthetic  related to ketamine. Its sale and use as a designer drug has been reported in various countries. It is an analogue of ketamine where the chlorine group has been replaced by fluorine. Due to its recent emergence, the pharmacological specifics of the compound are mostly unclear, but effects are reported to be similar to its parent compound, ketamine.

## History

The synthesis of 2-FDCK was first described in a 2013 paper as part of a larger effort to synthesize and evaluate new anesthetic drugs based on ketamine and its analogues. Ketamine itself was first introduced in 1964 and was approved for clinical use in 1970. Since then it has become one of the most important and applicable general anesthetics as well as a popular recreational drug.
The use of 2-FDCK as a research chemical has been reported in various countries. Many of these new psychoactive substances (NPS) appear on the drug market in order to circumvent existing drug policies. 2-FDCK was first formally notified by the EMCDDA in 2016, alongside 65 other new substances. Due to its recent appearance, little research has been done on the compound so far.
In January 2023, Israeli Biotech company "Clearmind Medicine Inc." announced the successful completion of a preclinical study examining 2-FDCK in a rat model of depression, with the compound outperforming ketamine in longevity of antidepressant effect.

## Chemistry

### Structure

The full chemical name of 2-FDCK is 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one.
2-FDCK belongs to a class of compounds called arylcyclohexylamines which contains various other drugs such as PCP and ketamine. Their general structure consists of a cyclohexylamine unit with an aryl group attached to the same carbon as the amine. 2-FDCK has an o-fluorophenyl group as an aryl substituent and the amine group is methylated. The cyclohexyl ring features a ketone group next to the amine position.
The chemical structure of 2-FDCK differs from ketamine only in that there is a fluorine atom attached to the phenyl group. Ketamine has a chlorine atom in that position.

### Synthesis

2-FDCK can be synthesized in a five-step reaction process. First 2-fluorobenzonitrile reacts with the Grignard reagent cyclopentyl magnesium bromide followed by a bromination reaction to obtain α-bromocyclopentyl-(2-fluorophenyl)-ketone. The reaction of the obtained ketone with methylamine at −40 °C then results in the formation of α-hydroxycyclopentyl-(2-fluorophenyl)-N-methylamine. Finally, the five-membered ring cyclopentanol form is expanded to a cyclohexylketone form by a thermal rearrangement reaction. HCl is used to create a water-soluble HCl salt of 2-FDCK.

### Detection

2-FDCK and its metabolites can be detected in urine with the use of liquid chromatography mass spectrometry (LC/MS).

## Pharmacology

### Metabolism

The metabolism of 2-FDCK is analogous to that of ketamine: the enzymes CYP2B6 and CYP3A4, the latter to a lesser extent, metabolise 2-FDCK to Nor-2FDCK via N-demethylation. This is further metabolised either to dehydronor-2FDCK by CYP2B6 or to hydroxynor-2FDCK by CYP2A6 and CYP2B6.
In general, the 2-FDCK equivalent shows stronger docking to CYP2B6 in simulations, as well as slower metabolism rate, than the more well-known ketamine. The lipophilicity is observed to be lower for 2-FDCK than for ketamine. In vitro to in vivo extrapolation predicts that in the body, 2-FDCK shows a lower intrinsic hepatic clearance than ketamine. Both of these characteristics would suggest that the effects of 2-FDCK last longer than those of ketamine.

### Pharmacodynamics

2-FDCK is structurally similar to ketamine, so a similar mechanism of action is expected, but there has been no study done to confirm this. Due to the halogen in the 2 position not being a chlorine but a fluorine, the molecule is more polar. This could influence binding to proteins, such as the NMDA receptor that ketamine primarily binds to and acts as an antagonist towards.

#### Comparison to other halogen-substituted ketamine variants

For general (halogen) substitutions of ketamine, docking strength for CYP2B6 follows the pattern H < Br < Cl < F. The parameter of internal clearance follows the pattern Br > Cl > F > H. Lastly, Km (Michaelis constant) follows the pattern of Br < Cl < F < H, and as such the in-vitro metabolism rate follows the inverse pattern, namely Br > Cl > F > H.

## Adverse effects

### Possible effects and dangers

In 2019, 2-FDCK was found in poisoned individuals in Hong Kong in combination with other ketamine-type drugs.

## Legal status

Due to the fast emergence of NPS, new substances such as 2-FDCK are often not yet specifically mentioned in controlled substance legislation. As a result, NPS are sometimes marketed as "legal highs". 2-FDCK is currently illegal in Italy Japan, Latvia, Singapore, Sweden, Switzerland, as well as being covered by blanket bans in Canada, Belgium, and the UK.
In October 2023 the ECDD recommended that 2-FDCK be added to Schedule II of the Convention on Psychotropic Substances of 1971.
`,
};
